☆ 4.6 Article

Identifying Predictive Biomarkers for Head and Neck Squamous Cell Carcinoma Response

CANCERS (2023)

Related references

Note: Only part of the references are listed.

Review Surgery

High expression of CMTM6 is a risk factor for poor prognosis of gastrointestinal tumors: A meta-analysis

Mengjie Dai et al.

Summary: A meta-analysis was conducted to evaluate the predictive effect of CMTM6 in malignant tumors. The results showed that high CMTM6 expression was significantly associated with shorter overall survival and progression-free survival in cancer patients, especially in gastrointestinal cancers. Additionally, high CMTM6 expression was correlated with lymph node metastasis and distant metastasis. These findings suggest that high CMTM6 expression could serve as a new diagnostic marker for poor prognosis and metastasis in malignant tumors.

ASIAN JOURNAL OF SURGERY (2023)

Add to Collection

Article Biotechnology & Applied Microbiology

Identification of an individualized therapy prognostic signature for head and neck squamous cell carcinoma

Cheng Lin et al.

Summary: This study aimed to construct a risk model based on therapeutic response-related genes (TRRGs) to predict therapy response and prognosis in TRRGs-defined subgroups of head and neck squamous cell carcinoma (HNSCC). By analyzing data from TCGA and GEO databases, differentially expressed TRRGs significantly associated with survival were identified, and a signature and prognostic nomogram based on TRRGs were established. The results showed that the model could effectively predict therapy response and overall survival in HNSCC patients.

BMC GENOMICS (2023)

Add to Collection

Article Oncology

Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial

Y. Tao et al.

Summary: This study aimed to evaluate the potential synergistic effect of pembrolizumab with radiotherapy compared with a standard-of-care cetuximab-radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). The results showed that pembrolizumab concomitant with radiotherapy did not improve tumor control and survival compared with cetuximab-radiotherapy, but it appeared to be less toxic in unfit patients with LA-SCCHN.

ANNALS OF ONCOLOGY (2023)

Add to Collection

Review Oncology

Etiology, diagnosis, treatment, and prevention of human papilloma virus-associated oropharyngeal squamous cell carcinoma

Hirotaka Shinomiya et al.

Summary: This review provides an overview of HPV-associated OPSCC from the perspectives of epidemiology, carcinogenesis, development, diagnosis, treatment, and prevention. The incidence of HPV-associated OPSCC is increasing, but the prognosis is favorable compared to classical OPSCC. Therefore, reducing treatment intensity for patients with HPV-associated OPSCC is being explored in large-scale trials.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Biochemistry & Molecular Biology

TRIM21 Expression as a Prognostic Biomarker for Progression-Free Survival in HNSCC

Amelie von Bernuth et al.

Summary: This study found that TRIM21 expression in head and neck squamous cell carcinoma (HNSCC) is associated with patient survival and tumor progression. High expression of TRIM21 is correlated with immune cell infiltration, higher tumor progression rate, and shorter survival time, suggesting it as a potential new prognostic biomarker.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Review Oncology

Role of tumor microenvironment in cancer progression and therapeutic strategy

Qingjing Wang et al.

Summary: Cancer is now recognized as a disease influenced by the tumor microenvironment (TME) rather than just a cellular and genetic disorder. Significant progress has been made in understanding the complexity of the TME and its impact on various anticancer therapies, particularly immunotherapies. Immunotherapy has shown promising therapeutic effects in treating solid tumors and hematological malignancies by leveraging the body's immune system to target and eliminate cancer cells. Recent advancements include the use of PD-1 and PD-L1 inhibitors, CAR-T cell therapy, and tumor vaccines. The TME plays a crucial role in tumor development, progression, and metastasis, making it an important focus for cancer immunotherapy research.

CANCER MEDICINE (2023)

Add to Collection

Article Immunology

Inflammatory response-related genes predict prognosis in patients with HNSCC

Si-li Jing et al.

Summary: By analyzing data from the TCGA database, we have constructed a novel signature consisting of 9 inflammatory response-related genes, which can reflect the immune status of HNSCC and be used for predicting disease prognosis. Additionally, these genes may serve as potential targets for HNSCC treatment.

IMMUNOLOGY LETTERS (2023)

Add to Collection

Article Genetics & Heredity

CTLA4 DNA methylation is associated with CTLA-4 expression and predicts response to immunotherapy in head and neck squamous cell carcinoma

Friederike Hoffmann et al.

Clinical Epigenetics (2023)

Add to Collection

Article Oncology

Diverging incidence trends of oral tongue cancer compared to other head and neck cancers in young adults in France

Sophie Deneuve et al.

Summary: The study found that the incidence of oral tongue cancer is increasing in young adults in France, while cancers of the remaining subsites of the oral cavity are declining. These trends may reflect changes in underlying exposures and emphasize the need for further investigation.

INTERNATIONAL JOURNAL OF CANCER (2022)

Add to Collection

Review Oncology

CMTM6, a potential immunotherapy target

Jie Liang et al.

Summary: CMTM6 has been identified as a novel regulator of PD-L1 expression in cancer, potentially playing a significant role in tumor immune escape and immunosuppression. Further studies are needed to explore the relationship between CMTM6 and PD-L1 in different tumors and diseases.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)

Add to Collection

Article Pathology

Biomarkers of response to checkpoint inhibitors beyond PD-L1 in lung cancer

Lynette M. Sholl

Summary: Immunotherapy is crucial in the management of non-small cell lung carcinoma, but responses vary widely. PD-L1 protein expression serves as a predictive biomarker, yet its sensitivity and specificity are suboptimal. Insights into tumor and host immune-specific factors are defining better immunotherapy biomarkers beyond immune checkpoint expression status.

MODERN PATHOLOGY (2022)

Add to Collection

Article Pathology

Prognostic potential of Akt, pAkt(Ser473) and pAkt(Thr308) immunoreactivity in relation to HPV prevalence in head and neck squamous cell carcinoma patients

Anna Janecka-Widla et al.

Summary: The study revealed pAkt(Thr308) as an important prognostic biomarker for HNSCC patients. Presence of active HPV16 infection, female gender, and low T stage were identified as independent favorable prognostic factors.

PATHOLOGY RESEARCH AND PRACTICE (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Overexpressed CMTM6 Improves Prognosis and Associated With Immune Infiltrates of Ovarian Cancer

Bo Yin et al.

Summary: CMTM6 is an important prognostic biomarker in ovarian cancer, and it is associated with immune cell infiltration and metabolism pathways.

FRONTIERS IN MOLECULAR BIOSCIENCES (2022)

Add to Collection

Article Oncology

Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma

Zhonghua Liu et al.

Summary: The study compared the PD-L1 expression in cytology samples and paired histologic samples of HNSCC, demonstrating high concordance in CPS and TPS scores between the two. This suggests that PD-L1 evaluation in cytology samples can serve as a feasible surrogate for determining eligibility for immunotherapy when histologic specimens are not readily available.

CANCER CYTOPATHOLOGY (2022)

Add to Collection

Review Oncology

HPV as a Carcinomic Driver in Head and Neck Cancer: a De-escalated Future?

James E. Bates et al.

Summary: Patients with HPV-associated oropharyngeal squamous cell carcinoma have better prognosis compared to those with non-HPV driven tumors. Both definitive radiotherapy and transoral robotic surgery are acceptable treatment options, but the decision should be made in a multi-disciplinary setting. Considering enrollment in clinical studies for treatment intensity de-escalation is recommended.

CURRENT TREATMENT OPTIONS IN ONCOLOGY (2022)

Add to Collection

Article Cell Biology

CMTM6 inhibits tumor growth and reverses chemoresistance by preventing ubiquitination of p21 in hepatocellular carcinoma

Yue Huang et al.

Summary: This study reveals that CMTM6 is significantly reduced in hepatocellular carcinoma (HCC) and predicts better prognosis. It demonstrates that CMTM6 inhibits HCC cell proliferation by blocking the G1/S phase transition and stabilizing p21 protein, leading to the inactivation of the pRB/E2F pathway. Additionally, CMTM6 sensitizes HCC cells to chemotherapy drugs and correlates positively with better clinical outcomes in postoperative recurrence treated with transarterial chemoembolization (TACE).

CELL DEATH & DISEASE (2022)

Add to Collection

Article Health Care Sciences & Services

TRIM24 Expression as an Independent Biomarker for Prognosis and Tumor Recurrence in HNSCC

Luise Klapper et al.

Summary: TRIM24 may serve as a novel prognostic biomarker for survival prognosis and early detection of local recurrences in HNSCC patients. It could be used for risk stratification and guiding follow-up examinations.

JOURNAL OF PERSONALIZED MEDICINE (2022)

Add to Collection

Article Oncology

The Current Burden of Oropharyngeal Cancer: A Global Assessment Based on GLOBOCAN 2020

Valentina Lorenzoni et al.

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2022)

Add to Collection

Article Biochemistry & Molecular Biology

CMTM6 attenuates cisplatin-induced cell death in OSCC by regulating AKT/c-Myc-driven ribosome biogenesis

Pallavi Mohapatra et al.

Summary: CMTM6 is a major driver of cisplatin resistance in oral squamous cell carcinomas. The study explores the detailed mechanism of how CMTM6 rewires cisplatin resistance by regulating the ribosome biogenesis network.

FASEB JOURNAL (2022)

Add to Collection

Article Oncology

Beta2-microglobulin(B2M) in cancer immunotherapies: Biological function, resistance and remedy

Hanbing Wang et al.

Summary: Cancer immunotherapies have made significant progress in recent decades, with techniques such as immune checkpoint inhibition and adoptive cell therapy showing impressive efficacy. However, resistance to these therapies still persists in some patients due to inadequate immune system priming. B2M, an important subunit of MHC class I, plays a critical role in tumorigenesis and immune control, and alterations in B2M gene and proteins have been linked to poor response to cancer immunotherapies. Promising therapeutic strategies are being developed to overcome these B2M-related limitations and enhance treatment efficacy.

CANCER LETTERS (2021)

Add to Collection

Article Pathology

Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer

Kenneth Emancipator et al.

Summary: Tumor proportion score (TPS) and combined positive score (CPS) are two methods used to evaluate PD-L1 expression, and CPS >= 50 appears to be equivalent to TPS >= 50% in predicting response rates. CPS may be more sensitive than TPS at lower cutoffs.

MODERN PATHOLOGY (2021)

Add to Collection

Article Biotechnology & Applied Microbiology

Immune Cell Landscape in Gastric Cancer

Yang Yang et al.

Summary: The study identified changes in immune cell composition between gastric cancer tissues and normal tissues. Certain immune cells, such as macrophages and Tregs, were found to be associated with gastric cancer prognosis. Additionally, the expression of immune regulatory factors in gastric cancer tissues did not follow their classical function, with some factors being overexpressed while others were underexpressed.

BIOMED RESEARCH INTERNATIONAL (2021)

Add to Collection

Article Oncology

Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment

Yanbin Zhao et al.

Summary: CMTM6 is reported to stabilize PD-L1 and enhance immunotherapy efficacy. It is expressed heterogeneously in various cancers with low mutation frequencies. CMTM6 expression is associated with PD-L1 protein expression and infiltration of immune cells in certain cancer types. Prognostically, CMTM6 shows significance in predicting overall survival in specific cancers.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Immunologic Cold Squamous Cell Carcinomas of the Head and Neck Are Associated With an Unfavorable Prognosis

Julika Ribbat-Idel et al.

Summary: The study identified significant differences in survival rates among HNSCC patients based on their tumor immune cell patterns, with immunologic hot and excluded patients showing better overall survival. Categorizing HNSCC as immunologic hot, cold, or excluded using a plain histological approach may serve as a potential prognostic tool.

FRONTIERS IN MEDICINE (2021)

Add to Collection

Article Oncology

Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancer

Chao Zhang et al.

Summary: High expression of CMTM6 and PD-L1 was found to be correlated with poor prognosis in gastric cancer patients, and the two proteins showed a positive correlation in gastric cancer tissues. Therefore, combined detection of CMTM6 and PD-L1 may serve as an indicator for assessing the prognosis of gastric cancer patients.

CANCER CELL INTERNATIONAL (2021)

Add to Collection

Article Oncology

CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer

Qi-Hua Peng et al.

Summary: CMTM6 is upregulated in colorectal cancer and is associated with lower pT stage, increased CD4(+)/CD8(+) tumor-infiltrating lymphocytes, and a favorable prognosis. PD-L1 is expressed at a low level in tumor tissues, and PD-L1 positivity in tumor stroma is associated with increased CD4(+) TIL density and a favorable prognosis. The coexpression status of CMTM6 and PD-L1 can stratify patients with CRC into different risk groups and may be especially useful for patients undergoing adjuvant chemotherapy.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Review Oncology

Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers

Vito Amodio et al.

Summary: A subset of colorectal cancers with mismatch repair deficiency are sensitive to immune checkpoint inhibitors, but some patients show primary resistance or develop acquired resistance. Changes in the Wnt and JAK-STAT signaling pathways, as well as alterations in the antigen presentation machinery, are associated with resistance to CPIs in these patients. Understanding the mechanistic basis of immune evasion in CRC provides rationale for innovative strategies to increase the subset of patients benefiting from CPIs.

CANCERS (2021)

Add to Collection

Article Oncology

OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway

Xin Pang et al.

Summary: In OSCC samples, higher expression of CMTM6 is associated with higher pathological stage, CD163+ macrophage infiltration, and PD-L1 expression. Knockdown of CMTM6 inhibits proliferative, migrative, and invasive abilities of OSCC cells, and suppresses M2 macrophage polarization in vitro by downregulating PD-L1 expression. Exosomal CMTM6 from OSCC cells promotes M2-like macrophage polarization via ERK1/2 signaling, indicating a novel crosstalk between cancer cells and immune cells in OSCC microenvironment.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

Add to Collection

Article Oncology

Targeting CMTM6 Suppresses Stem Cell-Like Properties and Enhances Antitumor Immunity in Head and Neck Squamous Cell Carcinoma

Lei Chen et al.

CANCER IMMUNOLOGY RESEARCH (2020)

Add to Collection

Article Cell Biology

Global burden of larynx cancer, 1990-2017: estimates from the global burden of disease 2017 study

Yujiao Deng et al.

AGING-US (2020)

Add to Collection

Article Oncology

Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study

Viktor Gruenwald et al.

ORAL ONCOLOGY (2020)

Add to Collection

Article Oncology

PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas

Mario Sanchez-Canteli et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)

Add to Collection

Article Oncology

Identifying predictors ofHPV-related head and neck squamous cell carcinoma progression and survival through patient-derived models

Nicole D. Facompre et al.

INTERNATIONAL JOURNAL OF CANCER (2020)

Add to Collection

Article Biochemistry & Molecular Biology

P16 expression and its association with PD-L1 expression and FOXP3-positive tumor infiltrating lymphocytes in head and neck squamous cell carcinoma

Taeyeong Kim et al.

MOLECULAR & CELLULAR TOXICOLOGY (2019)

Add to Collection

Article Oncology

Epidemiology of head and neck cancer in Germany

Antje Wienecke et al.

ONKOLOGE (2019)

Add to Collection

Article Oncology

Infiltration of FoxP3+Regulatory T Cells is a Strong and Independent Prognostic Factor in Head and Neck Squamous Cell Carcinoma

Imelda Seminerio et al.

CANCERS (2019)

Add to Collection

Article Oncology

Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group

T. Eder et al.

EUROPEAN JOURNAL OF CANCER (2019)

Add to Collection

Article Oncology

Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age

Nabil F. Saba et al.

ORAL ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness et al.

LANCET (2019)

Add to Collection

Article Oncology

Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer

Jon Zugazagoitia et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

Add to Collection

Article Pathology

Predictive value of PD-L1 diagnostics

H. -U. Schildhaus

PATHOLOGE (2018)

Add to Collection

Article Medicine, Research & Experimental

IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade

Mark Ayers et al.

JOURNAL OF CLINICAL INVESTIGATION (2017)

Add to Collection

Article Multidisciplinary Sciences

CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity

Marian L. Burr et al.

NATURE (2017)

Add to Collection

Article Oncology

UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses

Darshan S. Chandrashekar et al.

NEOPLASIA (2017)

Add to Collection

Review Oncology

The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis

Emma J. de Ruiter et al.

ONCOIMMUNOLOGY (2017)

Add to Collection

Article Dentistry, Oral Surgery & Medicine

Akt2 and p-Akt overexpression in oral cancer cells is due to a reduced rate of protein degradation

Prakasit Archewa et al.

JOURNAL OF INVESTIGATIVE AND CLINICAL DENTISTRY (2017)

Add to Collection

Article Oncology

Phosphorylation of AKT(Ser473) serves as an independent prognostic marker for radiosensitivity in advanced head and neck squamous cell carcinoma

Christian Freudlsperger et al.

INTERNATIONAL JOURNAL OF CANCER (2015)

Add to Collection

Article Dentistry, Oral Surgery & Medicine

p-Akt and its relationship with clinicopathological features and survival in oral squamous cell carcinoma: an immunohistochemical study

Helder Antonio Rebelo Pontes et al.

JOURNAL OF ORAL PATHOLOGY & MEDICINE (2015)

Add to Collection

Article Multidisciplinary Sciences

Analysis of Marker-Defined HNSCC Subpopulations Reveals a Dynamic Regulation of Tumor Initiating Properties

Paloma Bragado et al.

PLOS ONE (2012)

Add to Collection

© Peeref 2019-2024. All rights reserved.